Literature DB >> 24144845

Universal newborn screening for haemoglobinopathies in Guadeloupe (French West Indies): a 27-year experience.

Christian Saint-Martin1, Marc Romana, Alix Bibrac, Karine Brudey, Vanessa Tarer, Lydia Divialle-Doumdo, Marie Petras, Lisiane Keclard-Christophe, Sandrine Lamothe, Cédric Broquere, Maryse Etienne-Julan.   

Abstract

OBJECTIVES: In Guadeloupe, an island in the French West Indies, a universal newborn screening programme for sickle cell disease and other abnormal haemoglobins was initiated in 1984. In 1990, a comprehensive sickle cell centre was established to carry on the management programme. We here report the main results from the newborn screening programme from 1984 to 2010, and consider how the establishment of the sickle cell centre affected the programme.
METHODS: All blood samples were screened for the haemoglobinopathies using two reference methods in a single reference diagnosis laboratory. DNA analyses were also performed for confirmatory tests and analysis of the globin gene status.
RESULTS: Between 1 January 1984 and 31 December 2010, 178,428 newborns were screened at birth, and 585 children were diagnosed with major sickle cell syndromes (ie. an overall incidence of 1 in 304 births). Sickle cell anaemia (haemoglobin SS disease) was the most frequently observed (1 in 575 births), followed by haemoglobin SC disease (1 in 771 births) and haemoglobin Sβ-thalassemia disease (1 in 4,243 births). Some other rare haemoglobin variants were also detected, the most common being HbD(Punjab). The establishment of a comprehensive sickle cell centre resulted in a significant improvement in the screening coverage (p < 0.001) and a significant reduction of the delay between diagnosis and the first medical visit (p < 0.001).
CONCLUSION: The universal screening programme has made it possible to establish the incidence of the major sickle cell syndromes in Guadeloupe, and the management centre has improved its efficiency.

Entities:  

Keywords:  Guadeloupe (FWI); Universal newborn screening; haemoglobinopathies; management programme

Mesh:

Substances:

Year:  2013        PMID: 24144845     DOI: 10.1177/0969141313507919

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  3 in total

1.  CAREST--Multilingual Regional Integration for Health Promotion and Research on Sickle Cell Disease and Thalassemia.

Authors:  Jennifer Knight-Madden; Marc Romana; Rinaldo Villaescusa; Marvin Reid; Maryse Etienne-Julan; Laurence Boutin; Gisèle Elana; Narcisse Elenga; Gillian Wheeler; Ketty Lee; Rosa Nieves; Althea Jones Lecointe; Marie-Laure Lalanne-Mistrih; Gylna Loko; Lisiane Keclard-Christophe; Marie-Dominique Hardy-Dessources
Journal:  Am J Public Health       Date:  2016-03-21       Impact factor: 9.308

2.  Newborn screening for sickle cell disease: technical and legal aspects of a German pilot study with 38,220 participants.

Authors:  Claudia Frömmel; Annemarie Brose; Jeannette Klein; Oliver Blankenstein; Stephan Lobitz
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

3.  Newborn Screening for Sickle Cell Disease in St. Vincent and the Grenadines: Results of a Pilot Newborn Screening Program.

Authors:  Shelly-Ann Williams; Beneka Browne-Ferdinand; Ynolde Smart; Kristen Morella; Susan G Reed; Julie Kanter
Journal:  Glob Pediatr Health       Date:  2017-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.